News

 
SiSaf Ltd Announces US$13.2 Million Series B Financing
Read More
 
Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium
Read More
 
SiSaf announces licencing agreement to develop gene therapy for rare bone disease
Read More
 
SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research
Read More

Cookies

This website uses cookies. By proceeding navigating on this page, you agree to the use of the cookies according to the terms of our Privacy Policy Find out more.